Association Between Fecal Microbiota Composition, Metabolite Concentrations, and Indoxyl Sulfate Levels

Launched by TUNGS' TAICHUNG METROHARBOUR HOSPITAL · Mar 13, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how the bacteria in our gut (known as the gut microbiome) and certain substances in the body relate to each other in people with chronic kidney disease (CKD) who are undergoing hemodialysis (a treatment for kidney failure). Researchers want to understand how changes in gut bacteria might affect the levels of harmful substances in the blood, which can be a concern for kidney patients. They will look at stool samples and blood from 60 participants to see how these factors interact.

To be eligible for the study, participants need to be between 18 and 80 years old, diagnosed with stage V CKD, and have been receiving hemodialysis for at least three months. Unfortunately, those who are pregnant, have had a kidney transplant, or have certain severe health conditions will not be able to take part. If you join the trial, you will help researchers learn more about the gut microbiome and its impact on health, potentially leading to better treatments for kidney disease in the future. The study is not yet recruiting participants, so there will be more information to come.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • age 18-80 years and
• • diagnosed with CKD stage V
• • currently receiving hemodialysis treatment\>3 months
• Exclusion Criteria:
• • pregnant or nursing women
• • patients with kidney transplant
• • severe infections
• • severe cardiac diseases
• • liver diseases
• • malignancy
• • autoimmune disorders
• • severe malnutrition
• • consumed any type of pre-or probiotics
• • had antibiotic therapy within 1 month
• • diagnosed irritable bowel syndrome
• • Crohn's disease
• • ulcerative colitis